# Oneness Biotech Co., Ltd. clinical trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Oneness Biotech Co., Ltd. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Oneness Biotech Co., Ltd.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/oneness-biotech-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07938827 | Evaluating the Efficacy and Safety of Inhaled SNS812 in Hospitalized Adults With Moderate to Severe COVID-19 | Oneness Biotech Co., Ltd. | Not applicable | Not yet recruiting | COVID-19, Moderate-to-severe COVID-19 | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938827) |
| August 21, 2026 | NCT07779239 | PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers | Oneness Biotech Co., Ltd. | Not applicable | Not yet recruiting | Diabetic Foot Ulcers (DFUs) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779239) |
| February 18, 2026 | NCT07417124 | Assess the Safety and Tolerability of SNS851 in Study Participants | Oneness Biotech Co., Ltd. | Phase 1 | Recruiting | Metabolic Disease | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417124) |
| August 1, 2024 | NCT06531512 | Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers | Oneness Biotech Co., Ltd. | Phase 2/3 | Active not recruiting | Diabetic Foot Ulcer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06531512) |
| May 3, 2024 | NCT06397911 | Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis | Oneness Biotech Co., Ltd. | Phase 2 | Recruiting | Atopic Dermatitis | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06397911) |
| July 19, 2023 | NCT05952986 | A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults | Oneness Biotech Co., Ltd. | Phase 1 | Unknown | Atopic Dermatitis | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05952986) |
| July 12, 2023 | NCT05941793 | A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients | Oneness Biotech Co., Ltd. | Phase 2 | Completed | Mild to Moderate COVID-19 | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05941793) |
| January 10, 2023 | NCT05677893 | A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV... | Oneness Biotech Co., Ltd. | Phase 1 | Completed | Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05677893) |
| June 29, 2022 | NCT05438251 | Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B) | Oneness Biotech Co., Ltd. | Phase 4 | Terminated | Diabetic Foot Ulcer (DFU) | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05438251) |
| April 12, 2022 | NCT05322525 | A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers. | Oneness Biotech Co., Ltd. | Phase 4 | Terminated | Venous Leg Ulcers (VLU) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05322525) |
| November 26, 2021 | NCT05135130 | Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer | Oneness Biotech Co., Ltd. | Observational | Completed | Diabetic Foot Ulcer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05135130) |
| September 28, 2021 | NCT05059509 | Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis | Oneness Biotech Co., Ltd. | Phase 2 | Completed | Atopic Dermatitis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05059509) |
| August 24, 2021 | NCT05018299 | Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma | Oneness Biotech Co., Ltd. | Phase 2 | Completed | Severe Asthma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05018299) |
| August 17, 2021 | NCT05008965 | Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma | Oneness Biotech Co., Ltd. | Phase 2 | Recruiting | Allergic Asthma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05008965) |
| July 14, 2021 | NCT04962139 | Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers | Oneness Biotech Co., Ltd. | Phase 3 | Terminated | Chronic Diabetic Foot Ulcers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04962139) |
| June 30, 2021 | NCT04945161 | A Randomized,Double-blind,Placebo-controlled Clinical Study to Explore the Mechanism of Action of ON101 Cream in Patients With DFUs. | Oneness Biotech Co., Ltd. | Not applicable | Completed | Diabetic Foot Ulcers | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04945161) |
| June 4, 2020 | NCT04413942 | Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis | Oneness Biotech Co., Ltd. | Phase 2 | Unknown | Atopic Dermatitis | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04413942) |
| February 2, 2015 | NCT02353273 | The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers | Oneness Biotech Co., Ltd. | Phase 1 | Completed | Diabetic Foot | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02353273) |
| January 27, 2015 | NCT02347228 | Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies | Oneness Biotech Co., Ltd. | Phase 1 | Terminated | Advanced Solid Malignancies | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02347228) |
| July 15, 2013 | NCT01898923 | Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers | Oneness Biotech Co., Ltd. | Phase 3 | Completed | Diabetic Foot | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01898923) |
| July 3, 2008 | NCT00709514 | Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers | Oneness Biotech Co., Ltd. | Phase 2 | Completed | Chronic Diabetic Foot Ulcer | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00709514) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 9 |
| Terminated | 4 |
| Recruiting | 3 |
| Not yet recruiting | 2 |
| Unknown | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetic Foot | 7 |
| Dermatitis, Atopic | 4 |
| COVID-19 | 2 |
| Asthma | 1 |
| Metabolic Diseases | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Foot Ulcer | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [Architecture firms in the United States](https://specstream.ai/data/businesses/architecture-firms/united-states)
- [Patio cover companies in the United States](https://specstream.ai/data/businesses/patio-cover-companies/united-states)
- [Elevator companies in the United States](https://specstream.ai/data/businesses/elevator-companies/united-states)
- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
- [Mental health clinics in the United States](https://specstream.ai/data/businesses/mental-health-clinics/united-states)
